News|Videos|November 16, 2026

Haley B. Naik, M.D., on the hidradenitis suppurativa guideline recommendations most likely to change clinical practice practice

Naik says a strong recommendation for infliximab and a call for routine pain assessment are the HS guideline changes most likely to change clinical practice.

The first joint guidelines of care for hidradenitis suppurativa (HS) from the American Academy of Dermatology (AAD) and the Hidradenitis Suppurativa Foundation contain 37 recommendations. Two of them stand out as most likely to change clinical practice, according to Haley B. Naik, M.D., M.H.Sc., a professor in the Department of Dermatology at the University of California, San Francisco, president of the Hidradenitis Suppurativa Foundation and co-chair of the work group that wrote the new guidelines. The guidelines were published on Oct. 2026 in the Journal of the American Academy of Dermatology.

Naik noted the strong recommendation for the use of infliximab, sold under Remicade and other brand names, in moderate to severe HS. Infliximab is used off-label for HS, and the guidelines acknowledge the recommendation rests on low-certainty evidence: one randomized trial of 33 patients and seven cohort studies covering 132 patients. The work group cited clinical experience with high-dose, high-frequency infliximab, along with large benefits across multiple outcomes and low potential risks.

Naik said the odds of an industry-sponsored trial of infliximab in HS are "slim to none" because the drug is off patent and three biosimilars are on the market. She said she hopes the strong recommendation will improve access to infliximab, particularly for patients with moderate to severe disease.

The second recommendation that Naik highlighted as practice changing is a good practice statement calling on clinicians to routinely ask patients with HS about pain, using tools such as a visual analog scale or a zero-to-10 rating at each visit. The guidelines report that 61% of patients with HS have moderate to severe pain, and Naik said pain limits patients' ability to function, attend school and work.

Naik said the recommendation reflects input from patients and advocacy groups as well as gaps in physician training. Little is known about what causes HS pain or how best to assess and treat it, a research gap that Naik said is ripe for investigation.


Related to this article